Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial - Concepedia

Concepedia

Publication | Closed Access

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

62

Citations

13

References

2008

Year

Robert J. Amato, William Shingler, Stuart Naylor, J. Jac, J. P. Willis, Somyata Saxena, Joan Hernandez-McClain, Richard Harrop

Clinical Cancer Research

Abstract

TroVax in combination with IL-2 was safe and well tolerated in all patients. The high frequency of 5T4-specific immune responses and good clinical response rate are encouraging and warrant further investigation.

References

	Year	Citations

Page 1